lifesciences@work

Health~Holland

# Expert Class

## Clinical Trials
## Regulatory Affairs

Programme • Information

When Friday 29 March 2019 | 12:00 – 18:00 hrs

Where Pivot Park Meeting centre, 'Panorma zaal & zaal 1',
Chesbrough building Kloosterstraat 9, Oss | www.pivotpark.com

Hosted by pivotpark

## Let us guide you in the right direction!

Date

- **29 March 2019**

Time Frame

- Starting at 12:00 hrs – ending at approx. 18:00 hrs

Venue

- Pivot Park Meeting centre, 'Panorma zaal & zaal 1',
  Chesbrough building Kloosterstraat 9, Oss | www.pivotpark.com

Audience

- Exclusively organized for Venture Challenge, Value Voucher, Medtech Partners, Biotech Partners, Take Off Alumni and new life sciences and medical technology startups

Topics

- **Clinical Trials:** Getting a clinical trial underway is no simple task. From patient recruitment to study completion, the drug maker or med tech developer must undertake a wide array of complex, and closely monitored operations, complying with regulations all the way. Trials become more global, patient groups more targeted, and investigator sites more widespread. Where to begin and how to set it up?

- Closely connected with Clinical Trials are Regulatory Affairs: The final hurdle – getting your drug, therapy or medical device approved and on the market. Talk with experts about the regulatory requirements in Europe and the rest of the world, since they are continually evolving and vary from one country to another. What does it take to navigating through the different regulatory landscapes?



Programme Features

- Presentations and personal experiences by renowned expert
- Speed Sparring and free 1-on-1 consultations
- Networking and making valuable mutual introductions

**Thank You!**

## Contributing Experts and Supporting Organisations

# Programme & Contributing Experts

12:00 – 12:30 hrs. Ready to welcome our participants with basic lunch

12:30 – 12:45 **Being a startup at the Pivot Park Science Campus**

**Rick Meurders**
Business Developer, Pivot Park
Offering lab and office space of any size with access to high-quality pharmaceutical R&D facilities and infrastructure and expertise.

12:45 – 13:45 **Introductions**

**Ellen de Waal**
Partner | LifeSciences@Work Accelerator, since 2008
Owner Publimarket 1989-2014 | Owner Science Affairs, since 2015
Communication Manager, IMI HARMONY Alliance | European Centre of Excellence for big data in Hematology, since 2017

**Who's who**
**Startups | Experts | Partners | Other**

By means of 2-minute pitches

13:45 – 14:15 **We don't give up | Don't you give up**

**Joep Rijnierse**
Medical Director, Amgen
Board Member, HollandBio
Chairman Working Group Real Life Data, Vereniging Innovatieve Geneesmiddelen

# Programme & Contributing Experts | continued

14:15 – 14:45 Break | Speed Sparring

14:45 – 16:45 **Expert Lectures & Interaction**

## About Clinical Trials: the good, the bad, the ugly

**Ronald van der Geest**
Managing Partner, 3D-PharmXchange

## Supporting Clinical Research questions

**Jackie Droste**
Manager, Radboud UMC Technology Center Clinical Studies Policy Quality and Support

## Clinical study case from a clinical-stage medical device company pioneering a restorative approach in heart valve therapy

**Luc Verhees**
Senior Vice President for Clinical, Pre-clinical and Medical Affairs, Xeltis



16:45 – 17:15 Speed Sparring

17:15 – 18:00 Wrap-up | Networking | Space for 1-on-1 consulting | Drinks

# Profiles Participating Startup Teams

in alphabetical order by company/organization name

## AGILeBiotics | www.agilebiotics.com

### Andreas Bastian

The continuous emergence of bacterial resistance is threatening the clinical use of last-resort antibiotics leaving patients in intensive care with no therapy options left. According to the World Health Organization (WHO) and the Infectious Disease Society of America (IDSA) the world is entering the post-antibiotic era, with limited therapy options left for patients infected by MDR pathogens. Nowadays, physician treat patience with toxic antibiotics, such as polymyxins. Without acceleration of antibiotic development, death rate will increase 10-fold by 2050, reaching 250.000 deaths in Europe and 10 million deaths worldwide. Innovative medicine is desperately needed (Source: CDC). AGILeBiotics is an early-stage pharmaceutical company which is developing novel and safe antibacterial for patients in intensive care units suffering from multidrug-resistant infections, such as ventilator-associated pneumonia (VAP), urinary tract infections (UTI), intra-abdominal infections or sepsis. Approach: Connecting knowledge and expertise, Understanding patients' needs and Designing novel antibiotics. The unique setting of AGILeBiotics is connecting essential knowledge and facilities, supports us in understanding the patience needs, drives us in finding innovative solutions, and facilitates the pre-clinical development of our novel antibiotics to treat patients in intensive care units.

— Venture Challenge Fall 2016 Alumnus

## CC Diagnostics | https://cc-diagnostics.com/

### Arnoud Huisman



In the western world, 10 million triage tests are performed in cervical cancer screening programs on an annual basis. In Europe, almost one million women are falsely diagnosed with having cervical cancer with
the use of today's available tests. This leads to an annual financial burden of €360 million per year for the European society and severe psychological distress for the woman. Implementation of the CC Diagnostics' methylation assay will decrease the number of false positives with 33%. As a result, we will save >€120 million of annual healthcare cost for the European society and prevent unneeded emotional stress for thousands of women.
CC Diagnostics collaborates with the research group of the UMCG. During 15 years of research, this group has identified unique tumor-suppressor genes. Small-scale validation of the best combination of genes show, using the methylation assay as a triage test, an 81% specificity and a 50% increase in reproducibility, which outperforms any triage test available, regardless which primary test has been used. CC Diagnostics will, in collaboration with the UMCG, validate this combination in a large-scale study with 3.600 samples; results of this study are expected Q4 2019. CC Diagnostics holds an exclusive worldwide license on the patent.

— Venture Challenge Spring 2017 Alumnus

## Colonova | www.colotechpharma.com (temporary)

**Ignacio Faustino**, Founder
**Ashmir Plantijn**, Founder

Colonova is a formulation development company that uses a patented colon specific delivery technology that provides complete release in the colon. We aim to work with big pharmaceutical companies and startups that focus on the fields of colon related diseases such as inflammatory bowel diseases, irritable bowel syndrome and colon cancer as well as companies in the clinical nutrition sector.
The technology has achieved full development and validation in patients showing to be totally safe and ready for clinical development. It helps to deliver therapeutic molecules and can be used to change the route of administration of biologics providing a more cost-effective solution.

- Founded in 2018

## ExoVectory | www.exovectory.com

**Jetty van Ginkel**, Founder

ExoVectory offers a platform technology to produce large DNA constructs tightly packaged into naturally secreted human exosomes. Exosomes are small (~100nm) lipid vesicles that are secreted by cells. Their biological purpose is intercellular communication by transferring RNA and proteins from one cell to the other. Over the past decade, exosomes have gained interest as therapeutic carriers, both being able to carry a therapeutic load and having regenerative capabilities of their own. Until now loading exosomes with therapeutically relevant DNA constructs was not possible.
ExoVectory's products can carry transgenes with sizes of up to 25kb in total and are invisible to the immune system. Our platform is compatible with allogenic, "off-the-shelf" therapies, but can also be implemented in personalized, autologous, approaches. Our product allows for systemic administration of gene therapy, as well as multiple rounds of treatment without adverse immune responses. In addition, due to increased bioavailability and the exosome's natural travel patterns, ExoVectory's product can penetrate deep into tissues and has the capability to reach and destroy metastasized and migrated tumor cells, making them perfect delivery vehicles. We identified two major routes of administration. First, exosomes can be purified in vitro and administered systemically or directly to the target site. Second, to prevent loss of product during purification and to ensure long term loaded exosome release, the producer cells can be directly implanted near the target site.

- Venture Challenge Fall 2018 Alumni

## Hybridize | www.lifesciencesatwork.nl/profile/hybridize/

### Anton Jan van Zonneveld, Founder

**Profile**: RNA-based solutions for viral problems. On a yearly basis, more than 80,000 patients worldwide suffering from end-stage renal disease obtain a lease-on-life by receiving a donated kidney, dramatically improving their quality of life. While immunosuppression is essential to avoid rejection of the donor kidney, it also dramatically increases the risk of infection. Especially problematic in this setting is BK virus (BKV), a normally latent virus of the kidney that replicates to clinical levels in 35% of kidney transplant patients. This can trigger irreparable kidney damage that severely limits graft function and lifetime, leading to premature kidney loss and a return to dialysis. At present, clinicians are defenseless against BKV, with immunosuppressive tapering allowing the immune system to combat BKV, albeit with increased risk of both graft rejection and loss.
At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression. Hybridize is a spin-off of the LUMC.

- Venture Challenge Spring 2018 Alumnus and Winner.

## IOVA | www.iovabiopharmaceuticals.com

### Marc van Moorsel, Founder

IOVA is the biopharmaceutical product: MICROLYSE. MICROLYSE enzymatically breaks down blood clots in small blood vessels (i.e. the microvasculature), for which to date, no specific treatment exists. IOVA pursues to receive market authorization for an orphan disease named Thrombotic Thrombocytopenic Purpura (TTP) that is characterized by life threatening attacks of microvascular thrombosis. However, MICROLYSE has the capacity to target all forms of microvascular thrombosis and could also be applied in early-stage macrovascular thrombosis as seen in heart attacks and stroke. IOVA is determined to change the future of microvascular thrombosis.

- Venture Challenge Fall 2018 Alumni

## Mercurna | www.mercurna.com

### Sander van Asbeck, Co-founder & CEO

Chronic kidney disease (CKD) is a great unmet clinical need, covering a wide-spectrum of diseases, commonly denominated by progressive, damaging inflammation of the glomerulus (the filter of the kidney). More than 850 million people are affected worldwide. These patients are at risk of developing end-stage renal disease (ESRD), requiring dialysis and/or kidney transplantation to remove toxins from their blood. To slow the progression to ESRD, currently numerous systemically acting drugs are being employed, which are known for their dose-limiting side-effects. As a consequence, current CKD treatments are often ineffective in stopping progression of the disease from early stage to late stage (dialysis). The CKD market for the Western world therefore surpasses US$ 200B.
Mercurna develops a first-in-class therapy to charter this market, based on the identification of a unique kidney-targeting peptide. Mercurna has already shown in mice, that this peptide, derived from an endogenous protein, is able to encapsulate and deliver mRNA specifically into the cells of the glomerulus, thereby avoiding systemic (side-) effects. In vitro models based on glomerular cells proved that from each delivered mRNA molecule several thousands of therapeutic protein are produced by the cells, without the inherent safety issues of other therapies based on genetic information.

## MoMO Medical | www.momomedical.com

### Jorien de Jonge, Communication Manager

Pressure ulcers are a major problem in healthcare. They cause pain, suffering and cost over €15 Billion in the EU each year. The best way to prevent these wounds is by regularly changing the position of the patient (repositioning). However, in practice this method leads to either undertreatment (more pressure ulcers) or overtreatment (time waste and patient inconvenience). This is caused by lack of information about how the patient has been lying in bed.
Momo Medical is a company that improves patient safety through technology by providing caregivers with the right information, at the right time. The primary application of its device helps nurses prevent pressure ulcers by means of a patient friendly monitoring system. Momo Medical believes that technology has an important support role in the healthcare sector. Good healthcare is all about people being able to help people. Technology can help caregivers by making the work safer, smarter, and more efficient.

## PhythoNext | (PNG Medical) | www.phytonext.nl

**Eral Osmanoglou**, Managing Director
**Allesia Cogottie**

Phytonext is a technology company located in the Food Valley (Wageningen, the Netherlands). We are specialized in selective extraction and particle engineering. Our technology platform provides a novel method for extraction of all natural, highly valuable and fragile compounds and a method for formulating these following your specification requirements. Phytonext is a novel extraction technology that is particularly suited for selective extraction of phytochemicals from natural material, for example vegetables. Many of these phytochemicals have functional properties that can substitute synthetic chemicals that are currently in use. These phytochemicals can thus provide natural solutions for the food, cosmetic and pharmaceutical industries.

Spin-off: Medicinal cannabis oil has limited availability, making it difficult for patients to get it and the price is high. An enormously growing number of patients are driven to cannabis oil from the illegal circuit, the quality of which is unreliable. PNG Medical uses a new extraction technology that makes it possible to develop a high-quality herbal drug product from medicinal cannabis.

## PredicaDX | | www.lifesciencesatwork.nl/profile/predica/

**William Leenders**, Founder



Predica: to personalize the population-based screening program cervical cancer and thereby prevent overdiagnosis and unnecessary treatment of healthy women who test positive in the current screening program. Predica is active in the field of diagnostics, prognostics and prediction of treatment response in oncology. With its first product, the CervicaDx test, the company will focus on detection of cervical cancer. With the CervicaDx test Predicta can measure activity of hrHPV, instead of merely the presence of the virus. It is the activity of the virus that is at the basis of cancer development. The test can be applied, as an additional test, on cervical scrapes that were already taken in the screening program, which makes the implementation of our test also very convenient. Apart from this, the CervicaDx test identifies if integration of the viral DNA in the host genome has occurred, a step which is considered the onset of cancer development. Using this information, a reliable risk assessment can be made about prognosis of disease. Predica is a spin-off company of the Radboudumc.

— Venture Challenge Spring 2018 Alumnus. NWO Take Off 1.

## Sagacity | www.sagacity-pharma.com

**Karen Malone**, Founder

Sagacity is focused on developing drugs for the prevention of Alzheimer's Disease. This requires a safe drug that gets to the brain and is of low burden to patients in terms of both cost and application. In our primary drug development program, small molecules blocking Tau aggregation will be optimized to lead stage. Upon development of our lead compounds, we will enter pre-clinical development, becoming investor-ready for more significant funding to complete Phase I/II studies in healthy persons at high risk of AD, as defined by biomarkers. Using a proprietary assay to screen the J&J compound library, we have obtained first-line hits, giving us the green light to proceed with our large-scale screen. At this time, we are working with J&J to spin out this early phase program, that will serve as the cornerstone of our portfolio.
In our primary drug development program for Tau aggregation inhibitors, compounds will be optimized to lead stage. Upon selection of our lead compounds, we will enter pre-clinical development, becoming investor-ready for more significant funding to complete Phase I/II studies in healthy persons at high risk of AD, as defined by biomarkers. To reach our next developmental milestone – completion of the hit-to-lead optimization- an investment of 600.000 is needed.

- Venture Challenge Spring 2018 Alumnus, BioBusiness Summer School 2016 Alumnus, Finance for Pharma Growth course Fall 2017 VU Alumus, Webit Festival 2018 Founder's Games Alumnus

## Skyline DX | www.skylinedx.com

**Árjan van Manen**, EVP Commercial Developer



SkylineDx is a high-tech commercial-stage biotech company headquartered in Rotterdam, the Netherlands and a commercial office and laboratory in San Diego, California, USA. The company uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility. With the focus on diagnostics, SkylineDx assists healthcare professionals in accurately determining the type or status of the disease or to predict a patient's response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient.

# UpyTher | www.lifesciencesatwork.nl/profile/upyther/

**Peter Paul Fransen**, Founder
**Geert van Almen**, Founder

UPyTher develops custom drug delivery solutions for conventional and next generation therapeutics. Our lead indication will revolutionize the treatment of peritoneal cancer, which is one of the deadliest cancers and affects hundreds of thousands of patients worldwide. Aggressive hyperthermic intraperitoneal chemotherapy (HIPEC) is considered standard of care but is also associated with poor therapeutic efficacy because it only allows short exposure to the drug. UPyTher offers a single shot therapy for peritoneal cancer that allows local continuous drug exposure to improve therapeutic efficacy, patient recovery and survival. Our platform is based on proprietary supramolecular polymer chemistry and consists of a modular hydrogel drug depot and a common chemotherapeutic drug. The unique features of this platform enable local therapy, prolonged release of a hydrophilic drug with enhanced tumor penetration, whereas comparable hydrogels for local drug delivery typically lack this combination. Moreover, our versatile hydrogel platform is compatible with various types of therapeutics including small molecule drugs and biologics. This has been shown in preclinical models of cardiac and renal disease and demonstrates the unrivalled potential of this technology for future expansion towards other indications.

— Venture Challenge Fall 2017 Alumnus

# Profiles LS@W Partners

## Loyens & Loeff | LS@W Partner| www.loyensloeff.com

### Jacobine van Beijeren, Lawyer

As a leading firm, Loyens & Loeff is the logical choice for a legal and tax partner if you do business in or from the Netherlands, Belgium, Luxembourg and Switzerland, our home markets. You can count on personal advice from any of our 900 advisers based in one of our offices in the Benelux and Switzerland or in key financial centres around the world. Thanks to our full-service practice, specific sector experience and thorough understanding of the market, our advisers comprehend exactly what you need. Keywords: Full-service practice; Legal and tax advice second to none; Independent with an international scope; Innovative and pragmatic; Focused and engaged.
Reference is made to the enclosed hand-out of the Loyens & Loeff PPT about Regulatory Affairs

## Progress-EXS | LS@W Partner| www.progress-exs.com

### Thijs Veerman, COO

**Progress Project Management and Engineering** is an independent consultancy company with clients in the pharmaceutical and biotechnology industries and in the healthcare sector. We operate internationally, providing project management, engineering, CMC, validation Lean/OPex and quality assurance services. Progress-PME employs about 40 pharmaceutical experts. www.progress-pme.nl



**Progress Executive Services** supports its clients in the life science and pharmaceutical industry with interim senior management and consultancy. We have a large network of senior interim executives that have ample experience at the top levels in the life science and pharmaceutical industry. We are specialized in the areas of general management, productions, quality assurance and business development and offer professionals at C-suite, management team, line-, project- and program management level. www.progress-exs.com

**Time-to-market (CMC) quick scan.** When the decision is made to take a lead-candidate drug into pharmaceutical development, all main functions needed for development are activated in parallel: the clinical development team starts designing the first clinical study, the preclinical development team starts designing the preclinical studies needed to be allowed to start a clinical study, and chemical-pharmaceutical development team starts drafting a manufacturing process for the drug, including development of analytical methods to assure the quality of the candidate product to be given to healthy volunteers or patients. Progress EXS developed and validated a time-to-market (CMC) quick scan to rapidly identify gaps in CMC development and propose mitigations to close these gaps effectively to prevent major delays in pharmaceutical development and unexpected costs.

# More profiles

in alphabetical order by company/organization name

## Ardena | www.ardena.com

**Rob Abbenhuis**, Director Operations
**Jos Rewinkel**, Senior Scientist

Ardena helps organizations navigate the drug development process from molecule to clinic.Ardena offers an integrated, flexible service encompassing drug substance production, dosage form manufacture, clinical logistics, bioanalysis and dossier development. In addition, it is at the leading edge of nanomedicine development. The Ardena precision particle engineering and characterisation technologies are the key to accessing this fast evolving, competitive market.
Ardena has a European development and manufacturing base, but a global reach. The vast experience and expertise in all stages of drug development, combined with their dossier-centric approach, help customers progress life-saving medicines to patients quickly and reliably.

## iClusion | www.iclusion.com

**Leon Holtkamp**

Speeding up drug development: “All patients should have access to all clinical trials”, that’s iClusion’s ideal. Today only 5% of patients participate in clinical trials, though more then 50% would like to. On top of that, quite specific (targeted) therapies are being developed, and the small target patient segments outweigh the efforts of increasing patient recruitment, increasing development timelines. Not to mention the administrative (regulatory) burden and old-fashioned logistics of clinical trials that hamper the drug development process. iClusion has the potential to fix this broken clinical trial system with its innovative trial infrastructure (TrialEye) for study start up and patient recruitment. Clinical trials and patients are interconnected through this very user-friendly interface, saving precious time for both study sponsor and study site. The operational effectiveness, using standardized & harmonized documents and automated & online procedures, make it possible for the whole study site network to initiate a clinical trial within a few weeks instead of months. Part of iClusion’s TrialEye for study sites is an always UpToDate user-friendly search engine MatchPoint, showing all ongoing oncology clinical trials, so every oncologist and their patient can reach every trial and thus leave no treatment option unused. Patients can be included right
away or referred if the trial is not ongoing in the specific site.

— Founded in 2018

# More profiles

Continued

## Real CMC | www.real-cmc.nl

**Rezu Alloza**, Pharmasist and founder

A Drug Development Project is a long path …full of risks. CMC aspects are part of the risks to be considered during development and need to be addressed early in the project.
ReAl CMC provides consultancy to pharma/biotech companies in the area of DRUG PRODUCT DEVELOPMENT, from non-clinical phase throughout clinical phases till commercialization.

- Founded in 2018

## Utrecht Holdings | https://utrechtholdings.nl/

**Genoveva Heldens**, Business Developer

Utrecht Holdings is the Knowledge Transfer Office (KTO) of Utrecht University and University Medical Center Utrecht. We are focused on the utilisation and commercialisation of academic research. We support scientists in creating, building and investing in innovations with a particular expertise in biotech, medtech, education and ICT.

# Overview Participants

in alphabetical order by last name

| | | | | |
|---|---|---|---|---|
| Rob | | **Abbenhuis** | | Ardena |
| Resu | | **Alloza** | | Real CMC |
| Geert | van | **Almen** | | UphyTher |
| Andreas | | **Bastian** | | AGILeBiotics B.V |
| Jacobine | van | **Beijeren** | | Loyens & Loeff |
| Allessia | | **Cogotti** | | PhytoNext/PGN Medical |
| Jackie | | **Droste** | | Radboud UMC |
| Ignacio | | **Faustino** | | Colotech |
| Peter Paul | | **Fransen** | | UphyTher |
| Ronald | van der | **Geest** | | 3D-PharmXChange |
| Jetty | van | **Ginkel** | | ExoVectory |
| Geneveva | | **Heldens** | | Utrecht Holdings |
| Chretien | | **Herben** | | LifeSciences@Work \| Health Holland |
| Arnoud | | **Huisman** | | CC Diagnostics |
| Leon | | **Holtkamp** | | iClusion |
| Jorien | de | **Jonge** | | MoMo Medical |
| Timo | | **Koopmans** | | (previously connected withLS@W startup Karveel - Co-founder)(University Utrecht) |
| Willeman | | **Leenders** | | PredicaDx |

# Overview Participants

Continued

| | | | | |
|---|---|---|---|---|
| Karen | | **Malone** | | SagaCity |
| Arjan | van | **Manen** | | SkyLine Dx |
| Rick | | **Meurders** | | Pivot Park |
| Marc | van | **Moorsel** | | IOVA |
| Eral | | **Osmanoglou** | | PhytoNext/PGN Medical |
| Jos | | **Rewinkel** | | Ardena/ChemConnections |
| Joep | | **Rijnierse** | | Amgen |
| Thijs | | **Veerman** | | Progress EXS |
| Luc | | **Verhees** | | Xeltis |
| Ellen | de | **Waal** | | LifeSciences@Work \| Science Affairs |
| Anton Jan | van | **Zonneveld** | | Hybridize |

## Speed Sparring

The Sparring sessions will take place during the breaks in 2 x 2 sessions of 10 minutes each.

- Round 1: from 14:50 – 15:00
- *5-minute switch*




- Round 2: from 16:45 – 17:15
- 5-minute switch



# About the L@SW Expert Classes

LS@W Expert Classes are a series of targeted workshops organized in close collaboration with industry experts on relevant topics for Life Sciences and Medical Technologies Startups. Expert Classes also offers 1-on-1 consultations with Mentors and LS@W Alumni to help you out, by sharing their expertise.

Expert classes are specially organized for alumni and participants of the Venture Challenge, Value Centre, MedtechPartners, BiotechPartner, MBI Life Sciences &Health, BioBusiness Summerschool and Take off participants. Startups not (yet) part of our LS@W community but who are interested in participating can send in a request to Ellen de Waal.

We thank our 2017/2018/2019 contributing Experts from:

Loyens & Loeff, Progress EXS, YesDelft, Amsterdam UMC-University of Amsterdam, CbusineZ, Agendia, Sanofi, TU Delft/Delft Enterprises, NLO, European Patent and Trademark Attorneys, DSM Global Business Incubator, TU/E Innovation Lab, Usono, Philips, M Ventures, RVO, Merck Ventures, 2-BBB, Aglaia BioMedical Ventures, Netherlands Enterprise Agency (RVO), BioGeneration Ventures, Kite Pharma EU, Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Axon, eNovITe, Thuja Capital, Technology Transfer Office, Erasmus MC, European Patent Office, InnovationQuarter, Luris, BioPartner Leiden, PSR Orphan Experts, Paul Janssen Futurelab Leiden, Utrecht Holding, MDxHealth, Julius Center THINC, UMC Utrecht, Vereniging Innovatieve Geneesmiddelen, UMotion, Sciences Affairs.



# About the LifeSciences@Work Accelerator

LifeSciences@Work – since 2008 - is the national accelerator for high potential start-ups in Life Sciences and Medical Technologies. We offer a customized programme to help innovators build their business:
The Venture Challenge, Expert Classes, the Value Center.

Powered by Heath-Holland, Top Sector Life Sciences & Health,
Laan van Nieuw Oost-Indië 334, 2593 CE The Hague, The Netherlands

www.lifesciencesatwork.nl | www.health-holland.com

Follow us on Twitter: @lsatw | @healthholland
Become a member of our LinkedIn Group: LifeSciences@Work Accelerator